keyword
https://read.qxmd.com/read/38503307/characterization-of-diclofenac-induced-renal-damage-in-normotensive-and-hypertensive-rats-a-comparative-analysis
#21
JOURNAL ARTICLE
Thaise Boeing, Alana Bittencourt F Lima, Maria Eduarda Busana, Luísa Nathália Bolda Mariano, Luisa Mota da Silva, Rita de Cássia Vilhena da Silva, Priscila de Souza
BACKGROUND: Diclofenac is the non-steroidal anti-inflammatory drug (NSAID) mostly prescribed worldwide, but it is highly associated with hypertension and acute kidney injury. Despite that, little information is available about the renal effects of diclofenac in hypertensive individuals, which led us to carry out this comparative study between the renal effects of this NSAID in normotensive (NTR) and spontaneously hypertensive rats (SHR). METHODS: Male Wistar NTR and SHR were orally treated with vehicle (V: 10 mL/kg) or diclofenac sodium (D: 100 mg/kg) once a day for 3 days...
March 19, 2024: Drug Research
https://read.qxmd.com/read/38478197/biodistribution-of-drug-ada-complexes-the-impact-of-immune-complex-formation-on-antibody-distribution
#22
JOURNAL ARTICLE
Eugenia Opolka-Hoffmann, Martin R Edelmann, Michael B Otteneder, Simon Hauri, Gregor Jordan, Peter Schrag, Martin Lechmann, Gerhard Winter, Roland F Staack
The clinical use of therapeutic monoclonal antibodies (mAbs) for the treatment of cancer, inflammation, and other indications has been successfully established. A critical aspect of drug-antibody pharmacokinetics is immunogenicity, which triggers an immune response via an anti-drug antibody (ADA) and forms drug/ADA immune complexes (ICs). As a consequence, there may be a reduced efficacy upon neutralization by ADA or an accelerated drug clearance. It is therefore important to understand immunogenicity in biological therapies...
March 13, 2024: AAPS Journal
https://read.qxmd.com/read/38477209/relationship-between-compound-%C3%AE-ketoacid-and-microinflammation-in-patients-with-chronic-kidney-disease
#23
JOURNAL ARTICLE
Zaobin Chen, Yongda Lin, Jiali Wang, Kaijin Yao, Yina Xie, Xiutian Chen, Tianbiao Zhou
Chronic kidney disease (CKD) refers to the presence of structural or functional abnormalities in the kidneys that affect health, lasting for more than 3 months. CKD is not only the direct cause of global incidence rate and mortality, but also an important risk factor for cardiovascular disease. Persistent microinflammatory state has been recognized as an important component of CKD, which can lead to renal fibrosis and loss of renal function, and plays a crucial role in the pathophysiology and progression of the disease...
February 19, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38476082/safety-tolerability-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-sunobinop-in-healthy-participants
#24
JOURNAL ARTICLE
Alessandra Cipriano, Ram P Kapil, Mingyan Zhou, Manjunath S Shet, Garth T Whiteside, Sandra K Willsie, Stephen C Harris
Sunobinop is an investigational, potent, selective partial agonist at the nociceptin/orphanin FQ peptide receptor in vitro. Three phase 1 studies were conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating single- and multiple-dose administration of sunobinop in healthy participants. Study 1 was a randomized, double-blind, placebo-controlled, single-ascending dose study. Study 2 was a randomized, double-blind, placebo-controlled, multiple-ascending dose study. Study 3 was a randomized, open-label, single-dose, 4-way crossover study of oral and sublingual sunobinop comparing morning (AM) and bedtime (PM) administration...
March 13, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38472610/when-will-the-glomerular-filtration-rate-in-former-preterm-neonates-catch-up-with-their-term-peers
#25
JOURNAL ARTICLE
Yunjiao Wu, Karel Allegaert, Robert B Flint, Sebastiaan C Goulooze, Pyry A J Välitalo, Matthijs de Hoog, Hussain Mulla, Catherine M T Sherwin, Sinno H P Simons, Elke H J Krekels, Catherijne A J Knibbe, Swantje Völler
AIMS: Whether and when glomerular filtration rate (GFR) in preterms catches up with term peers is unknown. This study aims to develop a GFR maturation model for (pre)term-born individuals from birth to 18 years of age. Secondarily, the function is applied to data of different renally excreted drugs. METHODS: We combined published inulin clearance values and serum creatinine (Scr) concentrations in (pre)term born individuals throughout childhood. Inulin clearance was assumed to be equal to GFR, and Scr to reflect creatinine synthesis rate/GFR...
March 12, 2024: Pharmaceutical Research
https://read.qxmd.com/read/38458768/dosing-time-dependent-difference-in-the-suppressive-effect-of-empagliflozin-on-the-development-of-mechanical-pain-hypersensitivity-in-diabetic-mice
#26
JOURNAL ARTICLE
Ai Sato, Sai Yasukochi, Naho Iwanaka, Tomoaki Yamauchi, Akito Tsuruta, Satoru Koyanagi, Shigehiro Ohdo
A problem for patients with diabetes is the rise of complications, such as peripheral neuropathy, nephropathy and retinopathy. Among them, peripheral neuropathy, characterized by numbness and/or hypersensitivity to pain in the extremities, is likely to develop in the early stages of diabetes. Empagliflozin (EMPA), a sodium-glucose cotransporter-2 inhibitor, exerts hypoglycemic effects by preventing glucose reabsorption in proximal tubular cells. EMPA can improve cardiovascular and renal outcomes in diabetic patients, but its suppressive effect on the development of diabetic neuropathy remains unclear...
March 8, 2024: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/38448766/dosing-lutetium-lu-177-dotatate-for-a-hemodialysis-patient
#27
Lindsay Taylor, Richard Meades, Ann-Marie Quigley, Christos Toumpanakis, Catriona Goodlad, Andrew Davenport
Lu177-dotatate (Lutathera™) is a radioactive drug approved for the treatment of adults with gastro-entero-pancreatic neuroendocrine tumors and is predominantly renally excreted. Currently all patients receive 7400 MBq (200 mCi), and there are no guidelines for treating hemodialysis patients. We measured radioactivity prior to and post administration of two cycles of Lu177-dotatate in a hemodialysis patient, and radiation exposure to staff. We reduced the standard 7400 MBq by 33% for the first cycle and patient radioactivity fell by 40% following postdilution hemodiafiltration started 6 h post dosing, and by 45% for the second cycle and radioactivity fell by 47% with postdilution hemodiafiltration started 5 h post administration...
March 6, 2024: Hemodialysis International
https://read.qxmd.com/read/38396718/effect-of-low-frequency-renal-nerve-stimulation-on-renal-glucose-release-during-normoglycemia-and-a-hypoglycemic-clamp-in-pigs
#28
JOURNAL ARTICLE
Marius Nistor, Martin Schmidt, Carsten Klingner, Caroline Klingner, Georg Matziolis, Sascha Shayganfar, René Schiffner
Previously, we demonstrated that renal denervation in pigs reduces renal glucose release during a hypoglycemic episode. In this study we set out to examine changes in side-dependent renal net glucose release (SGN) through unilateral low-frequency stimulation (LFS) of the renal plexus with a pulse generator (2-5 Hz) during normoglycemia (60 min) and insulin-induced hypoglycemia ≤3.5 mmol/L (75 min) in seven pigs. The jugular vein, carotid artery, renal artery and vein, and both ureters were catheterized for measurement purposes, blood pressure management, and drug and fluid infusions...
February 7, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38394513/status-epilepticus-resulted-in-rhabdomyolysis-induced-aki-associated-with-hepatotoxicity-induced-by-synergistic-carbamazepine-and-diazepam-a-case-report
#29
JOURNAL ARTICLE
Nawwar Soliman, Mohammad Alsultan, Ayham Alhusseini, Omar Alsamarrai, Kassem Basha
RATIONALE: Rhabdomyolysis is a serious complication of status epilepticus (SE) caused by muscle cell damage and can lead to a life-threatening acute kidney injury (AKI). PATIENT CONCERNS: A 35-year-old man with a history of seizures treated with 3 different antiepileptic drugs (carbamazepine, lamotrigine, and levetiracetam) presented with SE. The patient received 5 doses of diazepam to control the SE in another hospital and was transferred to our emergency due to AKI...
February 23, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38374541/elimination-profile-of-low-dose-chlortalidone-and-its-detection-in-hair-for-doping-analysis-implication-for-unintentional-non-therapeutic-exposure
#30
JOURNAL ARTICLE
Detlef Thieme, Kai Weigel, Patricia Anielski, Aniko Krumbholz, Frank Sporkert, Annekathrin M Keiler
Chlortalidone (CLT) is a thiazide-type diuretic with high affinity for the erythrocyte carbonic anhydrase. Therapeutically, it is mostly used to treat edema and hypertension due to liver cirrhosis, heart insufficiency, or renal dysfunction. Although diuretics and masking agents are prohibited by the World Anti-Doping Agency (WADA) at all times in sports, substances belonging to this category are constantly detected in athlete samples, according to WADA's annual testing figures. Within this group of structurally diverse compounds, a threshold of 20 ng/mL has been introduced for six substances solely due to their presence as contaminants in other permitted drugs because of pharmaceutical production processes...
February 19, 2024: Drug Testing and Analysis
https://read.qxmd.com/read/38360626/efficacy-and-safety-of-enavogliflozin-vs-dapagliflozin-as-add-on-therapy-in-patients-with-type-2-diabetes-mellitus-based-on-renal-function-a-pooled-analysis-of-two-randomized-controlled-trials
#31
JOURNAL ARTICLE
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park
BACKGROUND: We assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes mellitus based on kidney function via pooled analysis of two 24-week, randomized, double-blind phase III trials. METHODS: Data from 470 patients were included (enavogliflozin: 0.3 mg/day, n = 235; dapagliflozin: 10 mg/day, n = 235). The subjects were classified by mildly reduced (60 ≤ eGFR < 90 mL/min/1...
February 15, 2024: Cardiovascular Diabetology
https://read.qxmd.com/read/38359644/optimization-and-validation-of-a-uplc-ms-ms-assay-for-simultaneous-quantification-of-2-8-dihydroxyadenine-adenine-allopurinol-oxypurinol-and-febuxostat-in-human-plasma
#32
JOURNAL ARTICLE
Unnur A Thorsteinsdottir, Hrafnhildur L Runolfsdottir, Finnur F Eiriksson, Inger M Sch Agustsdottir, Vidar O Edvardsson, Runolfur Palsson, Margret Thorsteinsdottir
Adenine phosphoribosyltransferase (APRT) deficiency is a rare , hereditary disorder characterized by renal excretion of 2,8-dihydroxyadenine (DHA), leading to kidney stone formation and chronic kidney disease (CKD). Treatment with a xanthine oxidoreductase inhibitor, allopurinol or febuxostat, reduces urinary DHA excretion and slows the progression of CKD. The method currently used for therapeutic monitoring of APRT deficiency lacks specificity and thus, a more reliable measurement technique is needed. In this study, an ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of DHA, adenine, allopurinol, oxypurinol and febuxostat in human plasma was optimized and validated...
February 5, 2024: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://read.qxmd.com/read/38321899/biodistribution-and-tumor-targeted-accumulation-of-anti-cea-loaded-iron-nanoparticles
#33
JOURNAL ARTICLE
Thais Silva Correa, William Gustavo Lima, Aline Beatriz do Couto Campos, Alexsandro Sobreira Galdino, Emilia Celma de Oliveira Lima, Valbert Nascimento Cardoso, Simone Odília Antunes Fernandes, Mariana Campos-da-Paz
INTRODUCTION: Active targeting of tumors by nanomaterials favors early diagnosis and the reduction of harsh side effects of chemotherapeuticals. METHOD: We synthesized magnetic nanoparticles (64 nm; -40 mV) suspended in a magnetic fluid (MF) and decorated them with anti-carcinoembryonic antigen (MFCEA; 144 nm; -39 mV). MF and MFCEA nanoparticles were successfully radiolabeled with technetium-99m (99mTc) and intravenously injected in CEA-positive 4T1 tumor-bearing mice to perform biodistribution studies...
February 6, 2024: Current Pharmaceutical Biotechnology
https://read.qxmd.com/read/38311833/results-from-a-phase-1-study-assessing-the-pharmacokinetics-of-the-aldosterone-synthase-inhibitor-baxdrostat-in-participants-with-varying-degrees-of-renal-function
#34
JOURNAL ARTICLE
Mason W Freeman, Yuan-Di Halvorsen, Mary Bond, Brian Murphy, Jonathan Isaacsohn
Baxdrostat is a selective small-molecule aldosterone synthase inhibitor in development for treatment of hypertension and chronic kidney disease. This phase 1, open-label, parallel-group study assessed the safety and pharmacokinetics (PK) of baxdrostat in participants with varying degrees of renal function. Participants were enrolled into control (estimated glomerular filtration rate [eGFR] ≥60 mL/min), moderate to severe renal impairment (eGFR 15-59 mL/min), or kidney failure (eGFR <15 mL/min) groups and received a single 10-mg baxdrostat dose followed by 7 days of inpatient PK blood and urine sampling...
February 4, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38305087/identification-and-characterization-of-an-endogenous-biomarker-of-the-renal-vectorial-transport-oct2-mate1
#35
JOURNAL ARTICLE
Yanrong Ma, Xinyi Wang, Xueyan Gou, Xinan Wu
The renal tubular organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1) mediate the vectorial elimination of many drugs and toxins from the kidney, and endogenous biomarkers for vectorial transport (OCT2-MATE1) would allow more accurate drug dosing and help to characterize drug-drug interactions and toxicity. Human serum uptake in OCT2-overexpressing cells and metabolomics analysis were carried out. Potential biomarkers were verified in vitro and in vivo. The specificity of biomarkers was validated in renal transporter overexpressing cells and the sensitivity was investigated by Km ...
February 2, 2024: Biopharmaceutics & Drug Disposition
https://read.qxmd.com/read/38291293/an-explanation-of-why-dose-corrected-area-under-the-curve-for-alternate-administration-routes-can-be-greater-than-for-intravenous-dosing
#36
JOURNAL ARTICLE
Hirokazu Wakuda, Yue Xiang, Jasleen K Sodhi, Naoto Uemura, Leslie Z Benet
It is generally believed that bioavailability (F) calculated based on systemic concentration area under the curve (AUC) measurements cannot exceed 1.0, yet some published studies report this inconsistency. We teach and believe, based on differential equation derivations, that rate of absorption has no influence on measured systemic clearance following an oral dose, i.e., determined as available dose divided by AUC. Previously, it was thought that any difference in calculating F from urine data versus that from systemic concentration AUC data was due to the inability to accurately measure urine data...
January 30, 2024: AAPS Journal
https://read.qxmd.com/read/38289075/effectiveness-and-safety-of-nirmatrelvir-ritonavir-in-kidney-transplant-recipients-with-severe-kidney-dysfunction-infected-with-covid-19
#37
JOURNAL ARTICLE
Hui Yang, Xin Yu, Wenjing Hou, Xiangduan Liu, Jiaojiao Chen, Ying Zhang, Ying Wang, Ying Zhu, Qing Qian, Kuifen Ma, Zhuoling An
Transplant patients face an elevated risk of coronavirus disease 2019 (COVID-19) morbidity and mortality and commonly encounter renal dysfunction. Nirmatrelvir is primarily excreted through the kidneys. The dosage of nirmatrelvir/ritonavir (NR) needs to be adjusted according to the degree of renal function impairment. Nevertheless, NR is not recommended for patients with severe renal impairment (estimated glomerular filtration rate < 30 mL/min) due to a dearth of associated research. In this study, we focus on kidney transplant patients and document and analyze the experiences of using NR in individuals with severe kidney dysfunction...
January 30, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38283440/novel-therapies-in-diabetes-a-comprehensive-narrative-review-of-glp-1-receptor-agonists-sglt2-inhibitors-and-beyond
#38
REVIEW
Olusegun A Olanrewaju, Fnu Sheeba, Avinash Kumar, Saad Ahmad, Narendar Blank, Reema Kumari, Komal Kumari, Tamara Salame, Ayesha Khalid, Nazdar Yousef, Giustino Varrassi, Mahima Khatri, Satish Kumar, Tamam Mohamad
Diabetes mellitus, a widespread metabolic illness with increasing global occurrence, continues to have a significant impact on public health. Diabetes is a condition marked by long-term high blood sugar levels. It is caused by a combination of genetic, environmental, and lifestyle factors, which lead to problems with insulin production and insulin resistance. This dysfunctional state disturbs the delicate balance of glucose regulation, promoting the emergence of problems in both large and small blood vessels that have a substantial impact on illness and death rates...
December 2023: Curēus
https://read.qxmd.com/read/38266453/study-on-tissue-distribution-metabolite-profiling-and-excretion-of-14-c-labeled-flonoltinib-maleate-in-rats
#39
JOURNAL ARTICLE
Ziyan Ma, Minghai Tang, Lijuan Chen
Flonoltinib Maleate (FM) is a dual-target inhibitor that selectively suppresses Janus kinase 2/FMS-like tyrosine kinase 3 (JAK2/FLT3), which is currently in phase I/IIa clinical trial in China for the treatment of myeloproliferative neoplasms (MPNs). In this research, we used [14 C]-labeled FM (14 C-FM) to investigate the distribution, metabolism, and excretion of FM in rats using High-Performance Liquid Chromatography coupled with High-Resolution Mass Spectrometry/Radioactivity Monitoring (HPLC-HRMS/RAM) and liquid scintillation counter...
April 15, 2024: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/38261609/role-of-transporters-and-enzymes-in-metabolism-and-distribution-of-4-chlorokynurenine-av-101
#40
JOURNAL ARTICLE
Waseema Patel, Ravi G Shankar, Mark A Smith, H Ralph Snodgrass, Munir Pirmohamed, Andrea L Jorgensen, Ana Alfirevic, David Dickens
4-Chlorokynurenine (4-Cl-KYN, AV-101) is a prodrug of a NMDA receptor antagonist and is in clinical development for potential CNS indications. We sought to further understand the distribution and metabolism of 4-Cl-KYN, as this information might provide a strategy to enhance the clinical development of this drug. We used excretion studies in rats, in vitro transporter assays, and pharmacogenetic analysis of clinical trial data to determine how 4-Cl-KYN and metabolites are distributed. Our data indicated that a novel acetylated metabolite ( N -acetyl-4-Cl-KYN) did not affect the uptake of 4-Cl-KYN across the blood-brain barrier via LAT1...
January 23, 2024: Molecular Pharmaceutics
keyword
keyword
106291
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.